Thermo Fisher is "very positive" about strategic mergers and acquisitions because these deals expand their capabilities.[1] The company expects revenue growth in the range of 3 to 6% for 2026 and 2027.[user] For 2028 and beyond, it expects growth of 7% or more.[user] At J.P. The 2026 Morgan Healthcare Conference was presented by Marc N. Casper, Chairman, President and CEO.[4][7] The firm continues a disciplined capital deployment strategy, including M&A and returning capital to shareholders.[2][4] In 2025, it achieved excellent operational performance and advanced its growth strategy.[4] For 2026, he expects improving demand trends in attractive market segments and strong growth in adjusted EPS.[4]